OncoSec Medical Incorporated Announces Proposed Public Offering of Common Stock
OncoSec Medical Incorporated Announces Proposed Public Offering of Common Stock |
[14-August-2020] |
SAN DIEGO and PENNINGTON, N.J., Aug. 14, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec") today announced that it intends to offer and sell shares of its common stock in a public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company intends to use the net proceeds from this offering for clinical, regulatory, manufacturing and, if and when approved, potential commercial activities of its product candidates; research and development activities, including potential acquisitions and in-licensing; and other general corporate purposes. ThinkEquity, a division of Fordham Financial Management, Inc., and Torreya Capital, LLC are acting as placement agents for the offering. A shelf registration statement on Form S-3 (File No. 333-233447) relating to the shares of common stock to be issued in the proposed offering was filed with the Securities and Exchange Commission (SEC) and is effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. A preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC. The securities may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained from ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673, by email at prospectus@think-equity.com. Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the SEC's website at http://www.sec.gov. About OncoSec Medical Incorporated TAVO™ is a trademark of OncoSec Medical Incorporated. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Forward-Looking Statements Company Contact Kellie Malloy
View original content to download multimedia:http://www.prnewswire.com/news-releases/oncosec-medical-incorporated-announces-proposed-public-offering-of-common-stock-301112807.html SOURCE OncoSec Medical Incorporated | ||
Company Codes: NASDAQ-SMALL:ONCS |
© 2020 PR Newswire. All Rights Reserved.